GlaxoSmithKline eyes €2.5B bond sale; Japanese tax rollback may trigger drug price cuts;

@FiercePharma: Merck KGaA to power India plant with coconut and cashew shells. Story | Follow @FiercePharma

@CarlyHFierce: AstraZeneca's Almirall buy yields its first new drug--and now, AZ has to sell it. More | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) is planning its first euro bond sales since 2009, thanks to ultralow borrowing costs in the currency. Report

> Japanese Prime Minister Shinzō Abe's decision to postpone a sales-tax hike may trigger annual drug price cuts, rather than the current biennial decisions. Report

> The Cubist Pharmaceuticals ($CBST) antibiotic Dificlir proved to be cost-effective in treating patients with Clostridium difficile infection, compared with the standard of care, according to a study. Report

> Eisai rolled out its breast cancer treatment Halaven in Brazil. Report

Medical Device News

@FierceMedDev: Congress considering bill to limit FDA regulation of EHRs, clinical decision support software. Story | Follow @FierceMedDev

@VarunSaxena2: RT @FierceMedDev: From FierceDrugDelivery: Survey raises the question: Do patients really know how to use drug delivery devices? Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: LabCorp and CareDx call it quits on partnership to develop lupus test. FierceDiagnostics story | Follow @EmilyWFierce

> Opponents of FDA's LDT regulations lawyer up, get in combat mode. Story

> WSJ: Ankle replacements look to be the next thing. More

> Strategic investors LabCorp, Envision put $15M into remote patient monitoring startup Vivify. Article

Biotech News

@FierceBiotech: Woodford's investment strategy may help change the global biotech scene. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Fledgling biotech upstart blends cutting-edge cancer immunotherapy strategies -- BeneVir. Article | Follow @JohnCFierce

@DamianFierce: It's almost as if Italian authorities don't care about biotech traders. More | Follow @DamianFierce

> Amgen, AstraZeneca's brodalumab beats J&J's Stelara in 2nd PhIII psoriasis showdown. News

> Biotech's Boston blitz is making lab space harder--and costlier--to come by. Story

> Novartis cans a researcher whose cooked data led to a slew of retractions. More

Drug Delivery News

> RNAi specialist Arrowhead reports loss of $58.7M in FY 2014. Item

> Singapore team combines cancer drugs, diagnostics in one biomarker nanoparticle. Report

> 'Hybrid' delivery vehicle gives DNA vaccines new potential. News

> Survey raises the question: Do patients really know how to use drug delivery devices? More

> Patients respond positively to Cynapsus film strip of apomorphine to combat Parkinson's. Article

Diagnostics News

> Curetis nabs $18M to support European Dx rollout, U.S. trial, possible IPO. News

> Illumina and bioMérieux to develop innovative sequencing system for infectious diseases. Article

> Indian startup develops low-cost, portable Dx for developing countries. Story

> LabCorp and CareDx call it quits on partnership to develop lupus test. Report

> Illumina teams up with Broad Institute, USAID for Ebola tracking. Item

Pharma Marketing News

> Who are the stars of personalized medicine? Roche, Novartis and J&J. Article

> From GPS inhalers to Jawbone data-gathering, some digital pharma inspiration. Story

> MannKind fans and critics line up for Sanofi's Afrezza pre-game show. More

> Ipsen on a hiring binge in U.S. to prep for new Somatuline marketing push. Story

> AstraZeneca's Almirall buy yields its first new drug--and now, AZ has to sell it. Article

And Finally... Almost one-quarter of cancer cases in the U.S. are linked to obesity, a World Health Organization report says. Report

Suggested Articles

Stephen Hahn, an oncologist who served as the chief medical officer for the MD Anderson Cancer Center, has secured Senate confirmation as FDA head.

As BMS searches for bright spots in its Opdivo-chemo combo fail from June, it’s zeroing in on squamous lung cancer patients who seemed to benefit.

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.